



Correction to: Cardiotoxicity of Targeted Cancer Drugs: Concerns, “The Cart Before the Horse,” and Lessons from Trastuzumab

Pierantonio Menna¹ · Giorgio Minotti^{1,2,3} · Emanuela Salvatorelli²

Published online: 15 April 2019
© Springer Science+Business Media, LLC, part of Springer Nature 2019

Correction to: Current Cardiology Reports (2019) 21:33
<https://doi.org/10.1007/s11886-019-1121-0>

In the original publication, there were two errors in Fig. 2. “Anhracyline” should be “Anthracycline” and “targetd” should be “targeted.”

The original article has been corrected.

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The online version of the original article can be found at <https://doi.org/10.1007/s11886-019-1121-0>

✉ Giorgio Minotti
g.minotti@unicampus.it

Pierantonio Menna
p.menna@unicampus.it

Emanuela Salvatorelli
e.salvatorelli@unicampus.it

¹ Clinical Pharmacology Unit, Campus Bio-Medico University Hospital, Rome, Italy

² Department of Medicine, Unit of Drug Sciences and Center for Integrated Research, University Campus Bio-Medico, Rome, Italy

³ Department of Medicine and Units of Drug Sciences and Clinical Pharmacology, University Campus Bio-Medico, Via Alvaro del Portillo, 21, 00128 Rome, Italy